Hairong Xu
ORCID: 0000-0001-9013-996XAlso affiliated with Chinese Academy of Sciences, Peking University, Beijing Jishuitan Hospital, Beijing Tian Tan Hospital, Center for Excellence in Brain Science and Intelligence Technology, Nanjing Drum Tower Hospital, Institute of Biophysics, Kite (United States), University of Chinese Academy of Sciences
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 3 papers. Top paper: “Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).”.
Frederick L. Locke, Zhen‐Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi +15 more
Hailin Wang, Zhen‐Huan Hu, Frederick L. Locke, Tanya Siddiqi, Caron A. Jacobson +18 more
Liuqin Jiang, Bexing Ye, Xiaoxue Shen, Ling Jiang, Ling Zhang +3 more